News & Updates

The first-in-class KRAS^G12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRAS^G12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.

The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.

First-line treatment with alectinib appears to produce sustained clinical benefit in Asian patients with advanced, ALK-positive nonsmall cell lung cancer (NSCLC) through 5 years of follow-up, according to long-term data from the phase III ALESIA presented at the ESMO Asia Congress 2022.

A gut microbiota–derived synbiotic formula developed by researchers from the Chinese University of Hong Kong (CUHK) is shown in a randomized controlled trial to reduce the risk of bacterial and viral infections, including COVID-19, reduce the risk of adverse events (AEs) after COVID-19 vaccination, restore healthy gut microbiota, and provide other health benefits.

The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.

Among people living with HIV (PLHIV), young women and patients with active syphilis appeared to be at an elevated risk of contracting COVID-19, according to a cross-sectional study presented at HIV Glasgow 2022.